These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2871374)

  • 1. Spironolactone metabolism and gynaecomastia.
    Overdiek JW; Merkus FW
    Lancet; 1986 May; 1(8489):1103. PubMed ID: 2871374
    [No Abstract]   [Full Text] [Related]  

  • 2. Gynaecomastia after spironolactone and potassium canrenoate.
    Bellati G; Idéo G
    Lancet; 1986 Mar; 1(8481):626. PubMed ID: 2869341
    [No Abstract]   [Full Text] [Related]  

  • 3. Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis.
    Mimidis K; Papadopoulos V; Kartalis G
    Scand J Gastroenterol; 2007 Dec; 42(12):1516-7. PubMed ID: 17907040
    [No Abstract]   [Full Text] [Related]  

  • 4. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
    Karagiannis A; Tziomalos K; Kakafika A; Florentin M; Athyros VG
    Nephrol Dial Transplant; 2007 Jan; 22(1):293. PubMed ID: 17018542
    [No Abstract]   [Full Text] [Related]  

  • 5. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone-induced gynaecomastia related to allergic reaction to "Darvon compound".
    Licata AA; Bartter FC
    Lancet; 1976 Oct; 2(7991):905. PubMed ID: 62134
    [No Abstract]   [Full Text] [Related]  

  • 7. Antialdosterones: incidence and prevention of sexual side effects.
    de Gasparo M; Whitebread SE; Preiswerk G; Jeunemaître X; Corvol P; Ménard J
    J Steroid Biochem; 1989 Jan; 32(1B):223-7. PubMed ID: 2913412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
    Greenblatt DJ; Koch-Weser J
    JAMA; 1973 Jul; 225(1):40-3. PubMed ID: 4740303
    [No Abstract]   [Full Text] [Related]  

  • 9. Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and began to hurt. My doctor agreed that I should stop taking spironolactone, but I wonder if I am missing out on something.
    Lee TH
    Harv Heart Lett; 2003 Oct; 14(2):8. PubMed ID: 14576040
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: Drug-induced gynaecomastia.
    Bridgman JF; Buckler JM
    Br Med J; 1974 Aug; 3(5929):520-1. PubMed ID: 4414195
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug-induced gynecomastia].
    Schirren U; Hinz B; Schirren C
    Andrologia; 1986; 18(1):104-7. PubMed ID: 3954080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gynecomastia and impotence: complications of spironolactone therapy.
    Greenblatt DJ; Koch-Weser J
    JAMA; 1973 Jan; 223(1):82. PubMed ID: 4739107
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathophysiology of spironolactone-induced gynecomastia.
    Rose LI; Underwood RH; Newmark SR; Kisch ES; Williams GH
    Ann Intern Med; 1977 Oct; 87(4):398-403. PubMed ID: 907238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unilateral gynecomastia and impotence during low-dose spironolactone administration in men.
    Zarren HS; Black PM
    Mil Med; 1975 Jun; 140(6):417-9. PubMed ID: 807887
    [No Abstract]   [Full Text] [Related]  

  • 16. Spironolactone-induced bilateral gynecomastia in a man detected by SPECT myocardial perfusion imaging.
    Farag AA; Andrikopoulou E; Hage FG
    J Nucl Cardiol; 2017 Apr; 24(2):742. PubMed ID: 27151301
    [No Abstract]   [Full Text] [Related]  

  • 17. [Controlled clinical trial for the comparison of tolerance of two aldosterone antagonists].
    Leizorovicz A; Guenaneche F; Luciani J; Boissel JP
    Therapie; 1991; 46(4):327-31. PubMed ID: 1948810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Iatrogenic gynecomastia in aldosterone-antagonist therapy].
    Quietzsch D
    Z Gesamte Inn Med; 1981 Feb; 36(3):87-9. PubMed ID: 7222857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone-induced gynecomastia.
    Cuculi F; Suter A; Erne P
    CMAJ; 2007 Feb; 176(5):620. PubMed ID: 17325324
    [No Abstract]   [Full Text] [Related]  

  • 20. [Gynecomastia in spironolactone therapy].
    Vetter H
    Dtsch Med Wochenschr; 1979 May; 104(21):762. PubMed ID: 446292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.